Organon & Co.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsOrganon & Co. is a global healthcare company focused on women's health and general medicines, including biosimilars, currently in the process of being acquired by Sun Pharma.
What they do
Organon sells over 70 products across women's health (contraception and fertility) and general medicines (biosimilars and established brands) in over 140 countries. It operates six manufacturing facilities in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the UK. Products are sold through wholesalers, retailers, hospitals, government agencies, and managed care providers.
Revenue drivers
- Women's Health — Includes Nexplanon, NuvaRing, Follistim AQ/Puregon; Q1 2026 revenue $389M, down 16% as-reported and 19% ex-FX, driven by Nexplanon U.S. decline of 28%.
- Biosimilars — Includes Hadlima, Renflexis, Brenzys, Tofidence, Ontruzant, Aybintio, Bildyos, Bilprevda; Q1 2026 revenue $173M, up 23% as-reported, 21% ex-FX, driven by Hadlima demand and new launches.
- Established Brands — Includes cardiovascular, respiratory, dermatology, non-opioid pain (e.g., Emgality, Vtama, Singulair, Dulera); Q1 2026 revenue $880M, down 1% as-reported, 7% ex-FX, with respiratory pricing pressure.
- Other — Includes third-party manufacturing sales; Q1 2026 revenue $18M, down 15% as-reported, 21% ex-FX.
Recent performance
Q1 2026 revenue was $1.460B, down 4% as-reported and 9% ex-FX year-over-year. Net income was $146M, diluted EPS of $0.55, and Adjusted EBITDA of $415M (28.4% margin). For Q2 2026 (latest 10-Q), revenue was $1.558B, net income $108M, diluted EPS $0.40. Full-year 2025 revenue was $6.22B, down from $6.40B in 2024; net income fell to $187M from $864M, partly due to restructuring and other items.
Strategy
Management is prioritizing debt reduction via lower dividends, product divestitures (e.g., Jada System sold to Laborie for up to $465M), and cost restructuring. They aim to improve net leverage and generate cash flow from the existing portfolio. The company is also pursuing collaborations with biopharmaceutical innovators, leveraging its commercial scale. In April 2026, Organon announced a pending all-cash merger into Sun Pharma, expected to close in early 2027.
Risks
- Material weaknesses in internal controls — The company identified material weaknesses in internal control over financial reporting, which could affect accurate and timely reporting, and has undergone an Audit Committee internal investigation.
- Merger execution and regulatory approval — The pending Sun Pharma merger is subject to regulatory approvals and stockholder approval; failure or delay could disrupt operations and focus.
- High leverage and debt service — Long-term debt was $8.48B as of June 30, 2026, against shareholder equity of $1.01B; high debt service limits financial flexibility.
- Tariffs and trade restrictions — Significant global operations expose Organon to tariffs and trade restrictions, which could materially affect costs, results, and cash flows.
Outlook
Organon is not providing financial guidance or hosting quarterly earnings calls due to the pending merger. The company expects the merger with Sun Pharma to close in early 2027, subject to closing conditions. The divestiture of the Jada System and cost savings initiatives are expected to strengthen the balance sheet and support debt reduction.